Company Profile
Aclarion Stock Price, News & Catalysts
- Ticker:
- ACON
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.32 USD (+1.75%)
Close
Last updated: August 12, 2026
8.62M USD
Market cap
Why the stock is moving
The latest company update was “Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process”. ACON changed 1.75% and closed at $2.32 on Aug 12, 2026, indicating a relatively limited closing-price reaction to this company update.
Company overview
Chronic Low-Back-Pain Diagnostics
Aclarion develops technology to help physicians identify which lumbar discs may be generating chronic low-back pain. Its approach combines magnetic resonance spectroscopy, biochemical biomarkers, signal processing and augmented-intelligence algorithms.
Nociscan Platform
Nociscan is a software-as-a-service platform that analyzes disc chemistry noninvasively and classifies discs as more likely painful or nonpainful. Physicians use the information alongside imaging and other diagnostic tools when selecting treatment targets.
Evidence and Reimbursement Strategy
Aclarion is supporting Nociscan with multiple clinical and real-world evidence studies. The evidence program is intended to demonstrate treatment-selection value and establish commercial-insurance coverage pathways.
Future catalysts
- Preliminary internal CLARITY trial readout expected in the second half of 2026.
- Public disclosure of early interim CLARITY results anticipated in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aclarion (ACON)?
Aclarion (ACON) most recently closed at 2.32 USD, a +1.75% move versus the previous session.
What is the market cap of Aclarion (ACON)?
Aclarion currently has a market capitalization of 8.62M USD on BioPharmSignal.
What does Aclarion do?
Chronic Low-Back-Pain Diagnostics Aclarion develops technology to help physicians identify which lumbar discs may be generating chronic low-back pain. Its approach combines magnetic resonance spectroscopy, biochemical biomarkers, signal processing and augmented-intelligence algorithms. Nociscan Platform Nociscan is a software-as-a-service platform that...
On which exchange is ACON stock listed?
Aclarion (ACON) is associated with NASDAQ, United States, Biopharma.
What is Chronic?
Chronic Low-Back-Pain Diagnostics Aclarion develops technology to help physicians identify which lumbar discs may be generating chronic low-back pain.
Which conditions is Aclarion targeting with Chronic?
Chronic Low-Back-Pain Diagnostics Aclarion develops technology to help physicians identify which lumbar discs may be generating chronic low-back pain. Its approach combines magnetic resonance spectroscopy, biochemical biomarkers, signal processing and augmented-intelligence algorithms. Nociscan Platform Nociscan is a software-as-a-service platform that...
How does Aclarion describe recent progress with Chronic?
Preliminary internal CLARITY trial readout expected in the second half of 2026. Public disclosure of early interim CLARITY results anticipated in the fourth quarter of 2026.
What is Low-Back-Pain?
Chronic Low-Back-Pain Diagnostics Aclarion develops technology to help physicians identify which lumbar discs may be generating chronic low-back pain.